SCHEMBL29620904

SCHEMBL29620904

Nc1nc(-c2ccc(C(F)(F)F)cn2)co1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.44
KDM4E B2RXH2 1/20 0.44
CASP3 P42574 2/20 0.42
KIF11 P52732 2/20 0.40
KMT2A Q03164 1/20 0.39
KDM1A O60341 1/20 0.38
MAOB P27338 1/20 0.38
ALDH1A1 P00352 1/20 0.38
RECQL P46063 1/20 0.38
TRPV3 Q8NET8 1/20 0.36
PTGS1 P23219 1/20 0.35
PDE2A O00408 1/20 0.35
LTA4H P09960 1/20 0.35
FBP1 P09467 1/20 0.35
DHFR P00374 1/20 0.34
ALOX5AP P20292 1/20 0.34
FEN1 P39748 1/20 0.34
HSD11B1 P28845 1/20 0.34
GCK P35557 1/20 0.34
GCKR Q14397 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16696512 0.81 NPSR1 (0.44) NPSR1KDM4ECASP3KIF11KMT2A
SCHEMBL2901258 0.80 LTA4H (0.53) NPSR1KDM4EKIF11KMT2AKDM1A
SCHEMBL811160 0.78 NPSR1 (0.53) NPSR1KDM4ECASP3KIF11KMT2A
SCHEMBL29595709 0.78 NPSR1 (0.53) NPSR1KDM4ECASP3KIF11KMT2A
SCHEMBL22925721 0.75 NPSR1 (0.47) NPSR1KDM4ECASP3KIF11KMT2A
SCHEMBL29620975 0.75 NPSR1 (0.47) NPSR1KDM4ECASP3KIF11KMT2A
SCHEMBL13662737 0.75 CCR1 (0.57) KDM1ALTA4HFBP1
SCHEMBL20391071 0.75 FBP1 (0.41) KDM1ALTA4HFBP1
SCHEMBL20390663 0.74 LTA4H (0.35) LTA4HFBP1
SCHEMBL22925608 0.73 CASP3 (0.56) NPSR1KDM4ECASP3KIF11KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001870-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2026-01-01 US disclosed
US-12448371-B2 Inhibitor compounds Cincera Therapeutics Pty Ltd (AU) 2025-10-21 US disclosed
CN-114450281-B Inhibitor compounds 辛塞拉治疗私人有限公司 2024-08-16 CN disclosed
US-20220274970-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-09-01 US disclosed
CN-114450281-A Inhibitor compounds 辛塞拉治疗私人有限公司 2022-05-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274970-A1 INHIBITOR COMPOUNDS SERPINB1, MMP1, SSB NPSR1 2967/4885KDM4E 1551/4885CASP3 1714/4885
US-20260001870-A1 INHIBITOR COMPOUNDS CES1, NCEH1, NR1H2 NPSR1 692/4885KDM4E 3025/4885CASP3 3467/4885
US-12448371-B2 Inhibitor compounds SERPINB1, MMP1, SSB NPSR1 2967/4885KDM4E 1551/4885CASP3 1714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.